OneDigital Investment Advisors LLC Reduces Holdings in Bruker Co. (NASDAQ:BRKR)

OneDigital Investment Advisors LLC reduced its position in Bruker Co. (NASDAQ:BRKR) by 25.5% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 3,640 shares of the medical research company’s stock after selling 1,246 shares during the period. OneDigital Investment Advisors LLC’s holdings in Bruker were worth $251,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Marshall Wace LLP raised its holdings in Bruker by 127.8% in the second quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock valued at $88,666,000 after acquiring an additional 779,549 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Bruker in the 2nd quarter worth about $36,472,000. AQR Capital Management LLC raised its stake in shares of Bruker by 123.6% in the 2nd quarter. AQR Capital Management LLC now owns 555,468 shares of the medical research company’s stock valued at $35,444,000 after purchasing an additional 307,021 shares in the last quarter. Vaughan Nelson Investment Management L.P. lifted its position in shares of Bruker by 78.3% during the second quarter. Vaughan Nelson Investment Management L.P. now owns 593,091 shares of the medical research company’s stock worth $37,845,000 after purchasing an additional 260,363 shares during the last quarter. Finally, Point72 Europe London LLP grew its stake in Bruker by 262.9% in the second quarter. Point72 Europe London LLP now owns 333,997 shares of the medical research company’s stock worth $21,312,000 after purchasing an additional 241,959 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bruker

In other news, CEO Frank H. Laukien bought 100,000 shares of the business’s stock in a transaction on Monday, November 18th. The stock was purchased at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 28.30% of the stock is owned by corporate insiders.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $57.07 on Friday. The firm’s 50 day moving average is $61.63 and its two-hundred day moving average is $64.77. The firm has a market capitalization of $8.65 billion, a P/E ratio of 27.44, a PEG ratio of 2.31 and a beta of 1.20. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. Bruker Co. has a 52 week low of $48.07 and a 52 week high of $94.86.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. During the same quarter in the prior year, the business earned $0.74 earnings per share. The firm’s revenue was up 16.4% compared to the same quarter last year. Analysts anticipate that Bruker Co. will post 2.4 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Monday, December 2nd will be given a $0.05 dividend. The ex-dividend date is Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.35%. Bruker’s dividend payout ratio is presently 9.62%.

Analysts Set New Price Targets

A number of research analysts have commented on BRKR shares. TD Cowen reduced their target price on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a report on Wednesday, November 6th. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Wells Fargo & Company lowered their target price on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. Citigroup reduced their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Finally, Barclays lowered their price objective on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Bruker currently has an average rating of “Moderate Buy” and an average price target of $79.36.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.